Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19906319 | 1.00 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18430098 | 0.85 | CA14 (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24149385 | 0.83 | GRIN2D (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15074258 | 0.82 | KMT2A (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10186174 | 0.82 | KMT2A (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15074250 | 0.82 | KMT2A (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28986517 | 0.80 | — | — | |
| SCHEMBL19906342 | 0.79 | SCN1A (0.35) | METAP2METAP1ALDH1A1TSHRTDP1 | |
| SCHEMBL23844012 | 0.78 | CA1 (0.45) | CA14CA12 | |
| Hydrochloric Acid SCHEMBL28986534 | 0.76 | CA1 (0.44) | CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890704-B1 | 2'-ETHYNYL NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9814739-B2 | 2′-ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170112868-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-9556216-B2 | 2′-Ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160289259-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20150232501-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| US-20140065101-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| WO-2014033617-A1 | 2'-ETHYNYL NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289259-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | EIF2AK2, WNK1, OXSR1 | GRIN2D 995/4885GRIN3B 884/4885GRIN1 832/4885 |
| US-20140065101-A1 | 2'-Branched Nucleosides for Treatment of Viral Infections | EIF2AK2, WNK1, OXSR1 | GRIN2D 995/4885GRIN3B 884/4885GRIN1 832/4885 |
| US-20170112868-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | EIF2AK2, NEK5, ERN2 | GRIN2D 809/4885GRIN3B 819/4885GRIN1 1507/4885 |
| US-20150232501-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | EIF2AK2, ERN2, NEK5 | GRIN2D 807/4885GRIN3B 846/4885GRIN1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.